Now I have sufficient calibration. Let me finalize the review.

**Round-1 bracket**: The paper is clearly stronger than the rejected Boltzmann generator papers (scores 2-3). It is substantially stronger than the mid-range papers (scores 4-6). Comparing to the best mid-range anchors (RegFlow at 6.67, PDNS at 6.50, CV-diffusion at 6.50), CMT offers a more fundamental theoretical contribution (analytical closed-form solutions under constraints, connection to annealing paths) and stronger empirical results (better absolute gains, larger molecular systems including a new benchmark). The paper is clearly above the 6.5 level but not at the 8+ level of the top anchors. **Bracket: 6.5-7.5.**

**Round-2 narrowing**: Comparing directly to RegFlow (6.67): CMT has stronger theory (analytic solutions vs. regression-based training of existing flows), comparable experiments (both on molecular systems, but CMT tackles larger systems including the new ELIL benchmark). CMT's weaknesses are minor overclaims. CMT is clearly a stronger paper. Comparing to PDNS (6.50): Similar level of methodological contribution, but CMT's experiments are on more challenging systems and the theoretical analysis is cleaner. CMT is slightly stronger. **Final score: 7.0.**

Now let me write the review.

Actually wait - let me reconsider. The harsh critic raises some valid concerns. The "consistently surpasses" language and the "2.5×" claim without qualification ARE somewhat overstated. The RAM TV on ELIL is genuinely worse than TA-BG. And the scalability claim about dimension-independent importance weight variance is stated without evidence in the main text. These are real but minor issues.

I think 7.0 is the right score. Let me write the review now.

Let me structure it:

## Summary
## Strengths
## Weaknesses
### Fatal (none)
### Major (none)
### Minor (a few)
### Trivial
## Nice-to-Haves
## Removed Points
## Novel Insights
## Suggestions
## Score and Decision

Now let me carefully consider what weaknesses to include and what to remove.

**Harsh Critic's Critical Issues:**

1. "Overstatement of the ESS improvement in the abstract" - VERIFIED. The abstract says "more than 2.5× higher effective sample size" without specifying which comparison. Against TA-BG on ELIL it's ~1.9×, on hexapeptide it's ~1.6×. Only vs FAB on ELIL is it 3.6×. This IS a minor overclaim. KEEP as Minor.

2. "The central scalability claim is not substantiated in the main text" - VERIFIED. The paper says "the trust-region constraint controls the variance of the importance weights, keeping it approximately constant, independent of the problem dimension d (see Appendix C.3)." The appendix is stripped from the parser version. This IS a real weakness - a key claimed advantage has no empirical support in the main text. However, the paper DOES reference the appendix where the justification presumably lives. I'll make this a Minor weakness (could be addressed by adding a brief empirical diagnostic in the main text).

3. "Inconsistency in the claim of 'consistently surpassing' baselines" - VERIFIED. The main results text says "Across all systems and metrics, our method outperforms the baselines" but CMT has worse RAM TV on ELIL (3.13e-2 vs TA-BG's 2.54e-2). This IS a factual overstatement. KEEP as Minor.

**Strength Finder claims - need to filter:**

1. "Analytical closed-form solutions" - KEEP. Specific, well-supported by Propositions 2.1-2.3.
2. "Consistent and substantial performance gains across all molecular benchmarks" - WEAKEN. The paper doesn't have consistent gains on RAM TV on ELIL. I'll rephrase to note that CMT achieves the best EUBO and ESS on every system, with particularly large gains on larger systems.
3. "Ablation study demonstrates both constraints are necessary" - KEEP. Well-supported by Figures 2 and 3.
4. "Introduction of ELIL tetrapeptide as new benchmark" - KEEP but note this is a supporting contribution.
5. "Negligible computational overhead" - KEEP. Supported by the 0.01% figure.
6. "Theoretical connection between constrained variational problems and annealing paths" - KEEP. Theorem 2.4.

Let me also handle the "Section-by-Section Notes" from the harsh critic - these contain some nice-to-have suggestions but also some observations. Let me keep the relevant ones.

OK, let me now produce the final review.Here is my synthesized final review.

## Summary

This paper introduces Constrained Mass Transport (CMT), a variational framework for sampling from unnormalized Boltzmann densities by constructing intermediate distributions under constraints on both KL divergence and entropy decay between successive steps. The authors derive closed-form solutions for the constrained optimization problems (Propositions 2.1–2.3) and establish their connection to geometric, tempered, and geometric-tempered annealing paths (Theorem 2.4). On four molecular systems including the newly introduced ELIL tetrapeptide (d=219), CMT is instantiated with normalizing flows and compared against FAB, TA-BG, and reverse/forward KL training. It achieves the best EUBO and ESS on every system, with ESS improvements of up to 1.6–3.6× over the strongest baselines on the largest systems.

## Strengths

- **Analytical closed-form solutions under principled constraints** — Propositions 2.1, 2.2, and 2.3 derive explicit expressions for the optimal intermediate densities under trust-region, entropy, and combined constraints. This is a clean theoretical contribution that directly characterizes how the constraints induce desired annealing paths, going beyond heuristic schedule design.

- **Strong and consistent empirical gains on EUBO and ESS across all systems** — Table 1 shows CMT achieving the best EUBO and ESS on every molecular system. On alanine hexapeptide (d=180), CMT attains 29.63% ESS vs. 18.22% for TA-BG (1.6×); on ELIL tetrapeptide (d=219), CMT attains 26.06% ESS vs. 13.75% for TA-BG (1.9×) and 7.21% for FAB (3.6×). The performance gap grows with system dimensionality, which is the most important trend.

- **Ablation study cleanly demonstrates that both constraints are necessary** — Figures 2 and 3 show that omitting either constraint leads to visible mode collapse in Ramachandran plots and degraded ESS between successive densities, while the combined geometric-tempered variant (9) avoids these failures. This is a convincing empirical validation of the method's core design choice.

- **Negligible computational overhead for the constraint satisfaction mechanism** — The Lagrangian dual optimization accounts for approximately 0.01% of total training time (alanine dipeptide), making the added cost of principled constraint enforcement essentially free.

- **Introduction of the ELIL tetrapeptide benchmark** — The paper introduces a 219-dimensional system with complex side-chain interactions, which the authors claim is the largest molecular system studied under the purely energy-based variational setting, providing a useful testbed for future work.

## Weaknesses

### Fatal
None.

### Major
None.

### Minor

1. **Overstatement of the ESS improvement in the abstract.** The abstract claims "more than 2.5× higher effective sample size" without qualification. This factor applies only when comparing CMT to FAB on the ELIL tetrapeptide (26.06% vs 7.21% → 3.6×). Against the stronger baseline TA-BG on the same system the factor is ~1.9×, and on alanine hexapeptide it is ~1.6× versus TA-BG. The claim is technically true for at least one comparison but is presented in a way that could mislead readers into inferring a larger universal advantage. *(Verification: Table 1 — CMT ESS 26.06% vs TA-BG 13.75% on ELIL = 1.9×; vs FAB 7.21% = 3.6×; CMT 29.63% vs TA-BG 18.22% on hexapeptide = 1.6×.)*

2. **"Consistently surpasses" claim is not fully supported by the RAM TV results on ELIL.** The main text states "Across all systems and metrics, our method outperforms the baselines," but on ELIL tetrapeptide, CMT's Ramachandran TV (3.13×10⁻²) is *worse* than TA-BG's (2.54×10⁻²). While CMT still dominates on EUBO and ESS, this single counterexample to the blanket "all metrics" claim should be acknowledged and discussed. *(Verification: Table 1 — RAM TV: CMT 3.13±0.03 vs TA-BG 2.54±0.13 on ELIL.)*

3. **Key scalability claim about dimension-independent importance weight variance lacks empirical support in the main text.** The paper asserts that "the trust-region constraint controls the variance of the importance weights, keeping it approximately constant, independent of the problem dimension d (see Appendix C.3)." This is a strong claim about the method's practical scalability, but no empirical diagnostic (e.g., ESS between successive intermediates plotted for two system sizes) is provided in the main body to support it. The appendix is referenced but not readable from the main text. Adding even a brief empirical illustration would substantially strengthen this claim. *(Verification: Section 3, line 153 — "the trust-region constraint controls the variance of the importance weights, keeping it approximately constant, independent of the problem dimension d (see Appendix C.3)". No figure or table in main text verifies this.)*

### Trivial

- The paper uses a fixed number of annealing steps for fair comparison but does not discuss sensitivity to this hyperparameter. A brief analysis of robustness to step count would be informative but is not required for the paper's core claims.

## Nice-to-Haves

- An empirical diagnostic plot showing ESS between successive intermediate densities for two system sizes (e.g., alanine dipeptide vs. hexapeptide) to support the dimension-independence claim.
- A brief intuitive explanation in the main text of why the trust-region constraint prevents exponential variance growth with dimension.
- A short discussion of why CMT underperforms TA-BG on RAM TV on ELIL — whether this reflects a genuine limitation, is within noise, or points to a specific mode coverage issue.

## Removed Points

The following points from the inputs were removed after verification:

- **"Missing related works"** — Removed per protocol: without external sources, I cannot verify which related works are missing.
- **"Proposition 2.2 yields tempered target independent of q_i"** confusion — The harsh critic noted this could be confusing to newcomers but acknowledged the paper addresses it; this is a presentation preference, not a weakness.
- **"Fixed-step schedule not discussed"** as a weakness — The paper explicitly states the fixed schedule is used for fair compute budget comparison (Section 5.1); this is a deliberate design choice, not an oversight.
- **Appendix-deferred content criticisms** (missing proofs, missing appendix content) — Removed per protocol: the parser strips appendices; the original submission contains them.
- **Strength Finder's generic/superficial strengths** (e.g., "this paper addressed an important problem", "this paper targeted an interesting question") — Removed as they lack specific evidence anchors.
- **Various formatting/typo nitpicks** — Removed per protocol (parser artifacts, not author errors).

## Novel Insights

None beyond the paper's own contributions. The reviewer inputs largely confirm the paper's framing rather than offering synthetic observations that transcend it. One observation worth noting: the design pattern of constraining *decay* (entropy decay) rather than absolute values (entropy itself) is a principled choice that elegantly avoids requiring knowledge of the target's entropy — this design philosophy could generalize beyond sampling to other sequential inference settings.

## Suggestions

1. **Clarify the ESS claim in the abstract** by specifying the comparison context (e.g., "achieving up to 3.6× higher effective sample size than the best baseline on the largest system").
2. **Add a brief empirical illustration of the dimension-independence claim** — even a small plot showing ESS(q_{i-1}, q_i) across annealing steps for two system sizes would validate this important scalability property.
3. **Discuss the ELIL RAM TV result** — acknowledge that TA-BG achieves a marginally better RAM TV on this one system and explain possible reasons (e.g., Ram TV measures only a 2D dihedral projection, and the global metrics EUBO/ESS are more reliable indicators of overall performance).
4. **Include a sensitivity study of the number of annealing steps** — showing that performance is robust to this hyperparameter would be a notable practical advantage.

## Score and Decision

**Calibration Summary:**

| Anchor | Avg Score | Round | Comparison |
|--------|-----------|-------|------------|
| 5Gtd4LOOZx (EWFM) | 2.50 | R1-low | Rejected Boltzmann sampler paper with limited novelty and weak baselines; CMT is much stronger |
| gqIv1sduP3 (Boltzmann neural samplers practicality) | 3.00 | R1-low | Rejected; CMT is clearly stronger in both theory and experiments |
| CEuzrRs613 (Perturbed Flow Matching) | 2.67 | R1-low | Rejected drug design paper; not directly comparable |
| qEzgXEBLIH (Physics-guided protein flows) | 2.00 | R1-low | Rejected; CMT is much stronger |
| 96fJALwotm (AIS complexity analysis) | 5.50 | R1-mid | Accepted; mostly theoretical with limited experiments; CMT has stronger empirical validation |
| aDJcWNmfce (Constrained Langevin) | 4.00 | R1-mid | Accepted poster; weaker empirical validation and theory-practice gap |
| 7GrUROKDyW (Annealed posterior sampling) | 6.00 | R1-mid | Accepted; theoretical contribution without experiments; CMT has both theory and experiments |
| ctdnzPxDI3 (RegFlow) | 6.67 | R2 | Accepted poster; comparable topic (NF for BGs). CMT has stronger theoretical contribution and comparable experiments on larger systems |
| 1bJN1EQByS (CV-enhanced diffusion) | 6.50 | R2 | Accepted poster; more of an integration contribution; CMT's theoretical contribution is more fundamental |
| XTHQqS7ObC (Proximal Diffusion) | 6.50 | R2 | Accepted poster; similar idea of breaking down sampling into subproblems. CMT has cleaner theory and experiments on more challenging molecular systems |

**Round-1 bracket**: [2.0, 6.67] → Narrowed to [6.5, 7.5]
**Round-2 narrowing**: CMT is clearly stronger than RegFlow (6.67) in theoretical contribution and at least comparable in empirical scope; stronger than PDNS (6.50) in theoretical clarity and molecular system complexity. The minor overclaims slightly temper the score.
**Final score**: 7.0

The paper presents a well-motivated, theoretically grounded framework with strong empirical support across multiple molecular systems. The weaknesses are limited to slightly overstated claims in the abstract and main text that can be corrected in revision without affecting the core contribution.

MY FINAL SCORE: <score>7.0</score>
MY FINAL DECISION: <decision>Accept</decision>